Irish Venture Capital: Sowing the Seeds - - BioPharm International

ADVERTISEMENT

Irish Venture Capital: Sowing the Seeds

BioPharm International


PHARMATRIN LIMITED

Based in Trinity College Dublin, Pharmatrin is developing a novel class of therapeutics known as indane dimers. The target therapeutic areas are organ transplant rejection and autoimmune diseases.

Investment: €1.5 million ($1.8 million)

Source: A consortium of investors that includes Growcorp, the Campus Companies Venture Capital Fund, and the Wellcome Trust. Other investors include Catalyst Biomedica, Trinity Venture Capital, Enterprise Ireland, and Trinity College Dublin.

STOKES BIO LIMITED

Stokes Bio develops microfluidics-based diagnostic systems for the genetic diagnosis of cancer. Childhood leukemia is the initial target disease, around which the microfluidics-based platform technology is developed. The Company is working in close collaboration with the Childhood Cancer Center of St Bartholomew's Hospital London, and the oncology department of the Regional Hospital Limerick.

Investment: €1 million ($1.17 million)

Source: The Cork-based venture capital firm, Kernel Capital Partners.

TriMed RESEARCH INC.

TriMed Research Ltd is an Irish-American biotechnology company based on technology spun out of the University of Nebraska Medical Center. TriMed is focused on therapeutic anti-infective products applied to the prevention of life-threatening infections of low birth weight infants and in immunosuppressed and oncology patients. The technology also has applications in the functional food and veterinary fields.

Investment: €5.0 million ($5.85 million)

Source: Seroba BioVentures and Inventages (Switzerland).

Web site: http://www.trimedres.com/


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here